Pruritus Therapeutic Market Size, Development Analysis, Key Trends, Growth Rate And Future Forecast (2024-2033)

The pruritus therapeutic market size has grown strongly in recent years. It will grow from $13.1 billion in 2023 to $14.2 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing prevalence of pruritus, advancements in research and development, growing aging population, expansion of healthcare infrastructure, increasing awareness among patients, collaborations and partnerships.

The pruritus therapeutic market size is expected to see strong growth in the next few years. It will grow to $19.7 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to continued research and innovation, emerging markets growth, rising healthcare expenditure, personalized medicine trend, regulatory support for innovation. Major trends in the forecast period include telemedicine and digital health integration, technological advancements, telehealth and digital health solutions, global regulatory landscape, biologics and immunomodulators, patient-centric approaches:.

Market Overview -
Pruritus therapeutic refers to the treatment of pruritus which refer to the uncomfortable feeling that makes a person want to scratch. It can be caused by a variety of factors, which include contact with an allergen, dry skin, pregnancy, and the body's reaction to a medicine.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=9925&type=smp

Rising Incidences Of Skin Disorders Propel Growth In The Pruritus Therapeutic Market
The increasing incidences of skin disorders are significantly contributing to the growth of pruritus therapeutic. Skin conditions refer to dermatologic conditions or skin disorders such as acne, eczema, skin cancer, psoriasis, and vitiligo that affect the skin. Pruritus therapeutics are used as a part of treatment for various skin diseases as most skin disorders have pruritus as a predominant symptom. For instance, in April 2022, according to the American Academy of Dermatology Association, a US-based association for dermatology, melanoma is expected to claim the lives of 7,650 people in 2022, including 5,080 males and 2,570 women. Additionally, in January 2023, according to the American Cancer Society, a US-based voluntary organization, In the United States, a projected 97,610 new melanoma cases will be diagnosed in 2023, with about 58,120 in men and 39,490 in women. Therefore, the increasing incidences of skin disorders will drive the pruritus therapeutic market.

Competitive Landscape -
Major companies operating in the pruritus therapeutic market report are Allergan plc, Astellas Pharma Inc., Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company, Galderma Laboratories LP, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Abbott Laboratories, Almirall SA, Eisai Co. Ltd., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Chemicals Ltd., Cara Therapeutics Inc., EPI Health LLC, AbbVie Inc., Actavis plc, Albireo Pharma Inc., Amgen Inc., Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Evelo Bioscience Inc., Huapont Life Sciences Co. Ltd., J&J Services Inc., LEO Pharma AS, MC2 Therapeutics Ltd., Mylan NV, Novan Inc., Ocera Therapeutics Inc., Trevi Therapeutics Inc., UCB SA, Viatris Inc., Teva Pharmaceutical Industries Ltd. .

Pioneering Product Developments Drive Momentum In The Pruritus Therapeutic Market
Product innovation is the key trend gaining popularity in the pruritus therapeutic market. Major companies operating in the pruritus therapeutic market are focusing on developing innovative medications and treatments for pruritus and related conditions. For instance, in August 2022, Maruho Co., Ltd. a Japan-based pharmaceutical company, launched the anti-IL-31 receptor, a humanized monoclonal antibody Mitchga Subcutaneous Injection 60 mg Syringes for the treatment of itching associated with atopic dermatitis. It is the first antibody drug that inhibits IL-31 signalling. IL-31 is a neuroimmune cytokine2 linked to pruritus and skin inflammation in the progression of atopic dermatitis3,4. The substance inhibits IL-31 binding to its receptor and inhibits itch and skin inflammation associated with atopic dermatitis.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

Key Segments -
The pruritus therapeutic market covered in this report is segmented -
1) By Type: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors, Others Types
2) By Disease Type: Atopic Dermatitis Or Eczema, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
3) By Application: External Use, Oral, Injection
4) By End Use: Hospitals, Clinics, Other Uses

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.